H.R. 4441 · 119th Congress · Health
Patient Access to Innovative New Technologies Act of 2025
- IntroducedJul 16, 2025 Done
- CommitteeReferred to 2 committees Current stage
- House floorNot yet Not reached yet
- Senate floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
Full text
No CRS summary yet · 317 wordsH.R. 4441 · Introduced in House · Jul 16, 2025
This Act may be cited as the Patient Access to Innovative New Technologies Act of 2025 .
(a) In general. Section 1886(d)(5)(K) of the Social Security Act ( 42 U.S.C. 1395ww(d)(5)(K) ) is amended by adding at the end the following new clause: (x) (I) A breakthrough device that is not approved, cleared, or authorized under section 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act by the deadline specified in section 412.87(f)(2) of title 42, Code of Federal Regulations (or a successor regulation) may be conditionally approved for the new technology add-on payment under this subparagraph for a particular fiscal year, effective for discharges beginning in the first quarter after receiving such approval, clearance, or authorization, provided that the approval, clearance, or authorization is granted before July 1 of the fiscal year for which the applicant applied for new technology add-on payments. (II) For purposes of this clause, the term breakthrough device means a medical device that— (aa) is designated for expedited development and priority review under section 515B of the Federal Food, Drug, and Cosmetic Act; and (bb) has been approved, cleared, or authorized under section 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act for the indication for which the designation described in item (aa) was made. (III) This clause shall not be considered an adjustment and shall be implemented in a budget neutral manner. .
(b) Effective date. This section, and the amendments made by this section, shall take effect on the enactment of this Act and shall apply to a breakthrough device (as defined in section 1886(d)(5)(K)(x)(II) of the Social Security Act, as added by subsection (a)) that is approved, cleared, or authorized under section 510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360(k) , 360c(f)(2), 360e) on or after July 1, 2023.
Shown here because the text is under 500 words. Open on Congress.gov
Who lobbies on it
1 organization · 10 filings · Q3 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Vantive Us Healthcare Llc
5 of 5 quarters
“Issues related to ESRD reimbursement H.R. 8319 - KIDNEY Remote Monitoring Act, Issues related to physician reimbursement for remote patient monitoring. H.R. 4441 - Patient Access to Innovative New Technologies Act, Issues related to sepsis device breakthrough designation.”
$1.4M lobbying spend in 2026 to date, all issuesQ3 2026 filing
Organizations that named H.R. 4441 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Jul 16, 2025Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Jul 16, 2025Introduced in House